A clinical-stage biotechnology company focused on transforming neuropsychiatric care through selective allosteric modulation
neurosterix.comLinkedInGeneva, SwitzerlandBiotechFounded 2024
25 sources · checked 2 times, last 1d ago
The source is a weekly roundup dated 13 November 2026, so the announcement date is recorded at week precision.
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $105M | 2026-11-11 | RTW Investments | 3 people on X · 21 outlets. #12 in Trending |
25 sources · checked 2 times, last 1d ago [ VERIFIED · CORRECTED ] read against 1 of 25 sources
The source is a weekly roundup dated 13 November 2026, so the announcement date is recorded at week precision. | ||||
3 people on 21 outlets
Neurosterix is targeting schizophrenia and mood/anxiety disorders where existing treatments can leave patients with limited relief and burdensome side effects. Its $105 million Series B follows completion of Phase 1 for NTX-253 and is intended to support Phase 2 while advancing a broader pipeline of selective allosteric modulators.
Checked against 9 sources yesterday
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $63M | 2024-04-04 | Perceptive Xontogeny Venture Fund II | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: finsmes.com, pulse2.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Found on X with Firecrawl search
Also named as backers in company research: Addex Therapeutics